Stay updated on 24-Week Secukinumab Efficacy for Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the 24-Week Secukinumab Efficacy for Psoriatic Arthritis Clinical Trial page.

Latest updates to the 24-Week Secukinumab Efficacy for Psoriatic Arthritis Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.8.0 to v3.8.1, while the study record content remains unchanged.SummaryDifference0.0%

- Check12 days agoChange DetectedThe record describes a completed Phase 3 trial evaluating secukinumab versus placebo for active psoriatic arthritis, including its design, outcomes, eligibility criteria, locations, and data-sharing plan.SummaryDifference85%

- Check19 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check33 days agoChange DetectedA site-wide NIH notice about transitioning from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The clinical trial record remains inaccessible behind a 403 error.SummaryDifference1%

- Check47 days agoChange DetectedThe footer revision identifier advances from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the previous study details, locations, and related content with an access notice. This reflects a shift from publicly viewable study information to an error page.SummaryDifference18%

Stay in the know with updates to 24-Week Secukinumab Efficacy for Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 24-Week Secukinumab Efficacy for Psoriatic Arthritis Clinical Trial page.